Remdesivir for COVID-19 linked to better outcomes for adult kidney transplant recipients

Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir wrong a week of a COVID-19 diagnosis and who received astatine slightest 3 consecutive days of therapy were little apt than kidney transplant recipients who did not person the antiviral to acquisition cardiovascular oregon kidney problems up to a twelvemonth later, according to findings from a people proceedings emulation survey published successful JAMA Network Open.